Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Using Reaxys for Lead Optimization: A Case Study

Posted on November 13th, 2015 by in Pharma R&D

Epigen Biosciences is a start-up pharmaceutical company that collaborates with academic groups to discover innovative drugs for a range of medical conditions, including renal diseases, cancer and CNS disorders. Co-founder Dr. Fabio Tucci met with Elsevier to discuss how Epigen researchers use Reaxys to support their application of advanced hit-to-lead and lead optimization methods. (more…)

More Drugs, Fewer Patients: Limits of Precision Medicine

Posted on November 9th, 2015 by in Chemistry

A number of targeted medications that are highly effective for a subgroup of patients with a particular disease have emerged in the last decade. These are often needed alternatives to debilitating therapies with uncertain outcomes. The small number of patients that benefit from such therapies, however, may pose a serious challenge looking into the future. (more…)

Speeding up Science: How We Can Stop the Decline of Drug Production as Scientific Information Increases

Posted on October 28th, 2015 by in Chemistry

Every 9 years, scientific output is doubling and more information is being made available to the world’s top scientists. Contrary to common sense and public opinion, for every 1 billion invested in drug development, the number of drugs approved has been halved every 9 years, and approximately 70% of drugs sold in the US today are generics. (more…)

Data, Data and More Data

Posted on October 23rd, 2015 by in Chemistry

Read an excerpt from the Elsevier whitepaper, Big Data, Wider Mindset to discover how systems biology and systems chemistry enable a holistic view of a biological system that is more than it’s sum of molecular components.

(more…)

  1. 1
  2. …
  3. 11
  4. 12
  5. 13